Author:
Li Weihua,Guo Lei,Liu Yutao,Dong Lin,Yang Lin,Chen Li,Liu Kaihua,Shao Yang,Ying Jianming
Funder
National Natural Science Foundation of China
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference46 articles.
1. RET, ROS1 and ALK fusions in lung cancer;Takeuchi;Nat Med,2012
2. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001;Shaw;Ann Oncol,2019
3. Efficacy of selpercatinib in RET-altered thyroid cancers;Wirth;N Engl J Med,2020
4. Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial;Shaw;Lancet Oncol,2019
5. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012
Cited by
75 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献